HC Wainwright Lifts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at HC Wainwright lifted their Q4 2026 earnings per share estimates for shares of TG Therapeutics in a report issued on Monday, August 3rd. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of $0.37 per share for the quarter, up from their prior estimate of $0.31. HC Wainwright has a “Buy” rating and a $78.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.42 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2028 earnings at $3.58 EPS, FY2029 earnings at $4.53 EPS and FY2030 earnings at $5.64 EPS.

Several other research firms have also recently issued reports on TGTX. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Bank of America increased their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Finally, B. Riley Financial boosted their price objective on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, TG Therapeutics has an average rating of “Hold” and a consensus target price of $58.67.

TG Therapeutics Stock Up 5.6%

TG Therapeutics stock opened at $48.74 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $59.30. The company has a market cap of $7.46 billion, a PE ratio of 17.04, a price-to-earnings-growth ratio of 1.18 and a beta of 1.62. The stock’s 50 day moving average price is $50.80 and its 200 day moving average price is $39.21.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million for the quarter, compared to analysts’ expectations of $229.77 million. TG Therapeutics had a return on equity of 73.23% and a net margin of 55.22%.The business’s quarterly revenue was up 70.2% on a year-over-year basis. During the same period last year, the company posted $0.17 earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in shares of TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in TG Therapeutics by 2.0% in the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 393 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in TG Therapeutics by 1.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 441 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in TG Therapeutics by 16.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 454 shares in the last quarter. Finally, HB Wealth Management LLC increased its holdings in TG Therapeutics by 6.7% during the 1st quarter. HB Wealth Management LLC now owns 7,514 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 475 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Second-quarter revenue rose 70.2% year over year to approximately $240 million, exceeding the roughly $230 million analyst estimate. BRIUMVI U.S. net product revenue reached approximately $228 million, demonstrating continued momentum in the multiple sclerosis franchise. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Management raised its 2026 total revenue target to approximately $950 million, above the prior outlook and the consensus estimate of about $941.7 million. The company also expects BRIUMVI U.S. revenue of approximately $890 million to $905 million. The CEO said the product remains on track to potentially become a $1 billion U.S. drug. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $77 price target, implying confidence in the long-term growth story. However, the firm reduced its EPS forecasts to $0.86 for 2026 and $2.16 for 2027, from $0.99 and $2.32, respectively. Its third-quarter 2026 estimate was also trimmed to $0.27 from $0.28. TG Therapeutics Analyst Estimate Changes
• Negative Sentiment: Second-quarter EPS was $0.05, well below consensus estimates ranging from $0.31 to $0.41 and down from $0.17 a year earlier. Manufacturing investments and other costs reduced near-term profitability, prompting investors to focus on the earnings miss despite strong sales growth. TGTX Q2 Earnings Lag, Sales Rise Year Over Year, 2026 View Raised

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.